# Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

> **NCT02536508** · PHASE3 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 627 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** BGF MDI 320/14.4/9.6 μg
- **DRUG:** GFF MDI 14.4/9.6 μg
- **DRUG:** BFF MDI 320/9.6 μg

## Key facts

- **NCT ID:** NCT02536508
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-10
- **Primary completion:** 2017-09-12
- **Final completion:** 2017-09-12
- **Target enrollment:** 627 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536508, "Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02536508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*